​

Funding Round

Series A - Firefly Bio

Series A - Firefly Bio

Investment Firm

Overview

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Announced Date

Feb 15, 2024

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Versant Ventures

Versant Ventures

Versant Ventures is a early_stage_venture and late_stage_venture and post_ipo firm.

MPM Capital

MPM Capital

MPM Capital is a early_stage_venture and late_stage_venture and private_equity and seed firm.

Participant Investors

4

Investor Name
Participant InvestorDecheng Capital
Participant InvestorMPM Capital
Participant InvestorEli Lilly
Participant InvestorVersant Ventures

Round Details and Background

Firefly Bio raised $94000000 on 2024-02-15 in Series A

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Company Funding History

1

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 15, 2024
Series A - Firefly Bio
4-94.0M

Recent Activity

There is no recent news or activity for this profile.